Azienda Provinciale Per I Servizi Sanitari — Clinical Trial Site

41 Registered trials

20 Currently recruiting

Organisation

Azienda Provinciale Per I Servizi Sanitari

Location

Trento, Italy

Identifier

ORG-100010272

Address

Via Alcide De Gasperi 79, 38123, Italy

Departments

#2003: U.O. di Oncologia Medica
Biologia Cellulare, Computazionale e Integrata
Cardiology Department
CISMED
Dipartimento di Oncologia Medica
Divisione di Oncologia Medica
Divisione Oncologia Medica
Ginecologia e Ostetricia Ospedale di Arco (TN)
Immunohematology and Transfusion Medicine Unit
Medical Oncology
Medical Oncology Department
Medicina Interna
Neurologia
Oncologia Medica
Oncology Unit
Ospedale Santa Chiara di Trento
U.O Oncologia Medica
U.O. di Oncologia Medica Ospedale S. Chiara -Trento
U.O. di Radioterapia Oncologica
U.O. Oncologia
U.O. Oncologia Medica
UO di Oncologia Medica
UO Gastroentrologia ed Endoscopia Digestiva
UO Oncologia Medica
UO Reumatologia

Clinical trials at this site (41)

Search interface

MENOPUR and REKOVELLE in Women UnderGoing an assisted reproductive technology cycle Pending

2022-500308-23-00 Infertility in women undergoing assisted reproductive t 11
Botulinumtoxin type A for treatment of Chronic Pelvic Pain Syndrome (CPPS): a phase 3 randomized, double blind, placebo-controlled, multi-ce… Pending

2023-506372-27-00 Adult patients, male or female, with chronic pelvic pai 5
Phase 3 trial of VMX-C001 vs usual pharmacological care in patients taking a FXa direct oral anticoagulant who require urgent surgery with o… Pending

2025-521632-12-00 Patients on Factor Xa inhibitor treatment needing an ur 5
A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36 Pending

2025-522084-15-00 metastatic NSCLC patients 10
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10… Recruiting

2024-512659-19-00 Advanced Melanoma 10 2025-03-31
AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting

2023-504214-30-00 Metastatic Castration-Sensitive Prostate Cancer (mCSPC) 5 2024-06-27
Trial of efficacy and safety of NS-229 versus placebo in patients with Eosinophilic Granulomatosis With Polyangiitis Recruiting

2023-504245-32-00 Eosinophilic granulomatosis with polyangiitis (EGPA) 4 2024-06-06
Nuwiq Dosing and outcomes In the ManagEment of women/girls with haemophilia A Needing FVIII treatment for Surgery – an International, Open-l… Recruiting

2022-502061-17-00 Haemophilia A 6 2023-12-15
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting

2024-519369-24-00 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER 5 2026-01-29
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants with Prostate Cancer Recruiting

2024-517653-27-00 Prostate Cancer 4 2025-12-17
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting

2025-520555-89-00 Metastatic castration-resistant prostate cancer (mCRPC) 5 2025-11-14
An open-label study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive pro… Recruiting

2024-520156-22-00 Metastatic hormone-sensitive prostate cancer 4 2025-10-08
CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZE… Recruiting

2024-517789-41-00 metastatic or locally advanced renal cell carcinoma 6 2025-07-04
REscue of Nephrons with ALe.F02 (RENAL F02) Recruiting

2022-502184-38-00 Rapidly progressive glomerulonephritis 4 2025-06-06
C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant… Recruiting

2024-511652-40-00 METASTATIC CASTRATION RESISTANT PROSTATE CANCER 5 2025-02-05
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer… Recruiting

2023-505616-38-00 Unresectable and/or Metastatic HER2-low or HER2 Immunoh 4 2024-09-04
Preventing caRdiovascular collapsE with VasoprEssors duriNg Tracheal IntubatiON: The PREVENTION Randomized Controlled Trial (PREVENTION tria… Recruiting

2023-503895-25-00 criticall illness 5 2024-08-01
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
ExclUsive endocRine therapy Or radiation theraPy for women aged ≥70 years with luminal A-like early stage breast cancer (EUROPA): a randomiz… Recruiting

2023-508094-88-00 breast cancer 5 2021-02-08
RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone orenzalutamide) as first-line… Recruiting

2024-518623-30-00 metastatic castration resistant prostate cancer without 6 2020-10-01